Related Experiment Video
Updated: Nov 10, 2025
Translational Orthotopic Models of Glioblastoma Multiforme
Published on: February 17, 2023
Contemporary Mouse Models in Glioma Research
William H Hicks1, Cylaina E Bird1, Jeffrey I Traylor1
1Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Abstract:
Despite advances in understanding of the molecular pathogenesis of glioma, outcomes remain dismal. Developing successful treatments for glioma requires faithful in vivo disease modeling and rigorous preclinical testing. Murine models, including xenograft, syngeneic, and genetically engineered models, are used to study glioma-genesis, identify methods of tumor progression, and test novel treatment strategies. Since the discovery of highly recurrent isocitrate dehydrogenase (IDH) mutations in lower-grade gliomas, there is increasing emphasis on effective modeling of IDH mutant brain tumors. Improvements in preclinical models that capture the phenotypic and molecular heterogeneity of gliomas are critical for the development of effective new therapies. Herein, we explore the current status, advancements, and challenges with contemporary murine glioma models.
Insights
Developing effective glioma treatments requires better animal models. This study reviews current murine models for glioma, focusing on challenges and advancements in modeling IDH-mutant brain tumors for preclinical research.
Area of Science:
- Neuro-oncology
- Translational research
- Preclinical modeling
Background:
- Glioma outcomes remain poor despite molecular pathogenesis understanding.
- Effective treatments necessitate accurate in vivo disease models and preclinical testing.
- Isocitrate dehydrogenase (IDH) mutations are common in lower-grade gliomas, driving the need for specific models.
Purpose of the Study:
- To explore the current status of contemporary murine glioma models.
- To highlight advancements in glioma modeling.
- To discuss challenges in developing and utilizing these models for therapeutic development.
Main Methods:
- Review of existing literature on murine models for glioma.
- Analysis of xenograft, syngeneic, and genetically engineered models.
- Focus on models capturing phenotypic and molecular heterogeneity, including IDH-mutant tumors.
Main Results:
- Various murine models (xenograft, syngeneic, genetically engineered) are utilized for glioma research.
- Progress has been made in modeling IDH-mutant gliomas.
- Significant challenges remain in fully capturing glioma heterogeneity.
Conclusions:
- Improvements in preclinical murine models are critical for advancing glioma therapy.
- Faithful modeling of glioma heterogeneity is essential for successful treatment development.
- Continued innovation in murine models is needed to overcome current therapeutic limitations.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
